Free Trial

Adial Pharmaceuticals Q1 2023 Earnings Report

Adial Pharmaceuticals logo
$0.65 -0.05 (-7.24%)
As of 04:00 PM Eastern

Adial Pharmaceuticals EPS Results

Actual EPS
-$2.75
Consensus EPS
-$3.50
Beat/Miss
Beat by +$0.75
One Year Ago EPS
N/A

Adial Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adial Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

Adial Pharmaceuticals Earnings Headlines

Adial Pharmaceuticals appoints new COO Tony Goodman
Equities Analysts Set Expectations for ADIL Q1 Earnings
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
See More Adial Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email.

About Adial Pharmaceuticals

Adial Pharmaceuticals (NASDAQ:ADIL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

View Adial Pharmaceuticals Profile

More Earnings Resources from MarketBeat